on opportunities with the goal of identifying novel products with high potential, or companies, for Celsion to acquire. Strategic alternatives the Company may pursue could include, but are not limited to, continuing its current operating plan, partnering or other collaboration agreements, acquisition of another company's business or assets, or a merger or other strategic transaction. There can be no assurance that the exploration of strategic alternatives will result in any agreements or transactions, or that, if completed, any agreements or transactions will be successful or on attractive terms. The Company does not intend to disclose developments with respect to this process except as required under applicable securities regulations.
About Celsion Corporation
Celsion is dedicated to the development and commercialization of innovative cancer drugs, including tumor-targeting treatments using focused heat energy in combination with heat-activated liposomal drug technology. Celsion has research, license or commercialization agreements with leading institutions, including the National Institutes of Health, Duke University Medical Center, University of Hong Kong, the University of Pisa, the UCLA Department of Medicine, the Kyungpook National University Hospital, the Beijing Cancer Hospital and the University of Oxford. For more information on Celsion, visit our website: http://www.celsion.com.
Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials; the significant expense, time, and risk of failure of cPage: 1 2 3 4 Related biology technology :1
. Celsion Corporation Announces $15 Million Registered Direct Offering2
. Todays Research on Celsion, Zogenix, Actavis, and Avanir Pharma3
. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results4
. Kensey Nash Corporation Announces Achievement of $6 Million Milestone From Spectranetics Corporation5
. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting6
. Neogen Corporation Announces 2nd Quarter Results Conference Call7
. Luminex Corporation to Present at JP Morgan Healthcare Conference8
. Luminex Corporation Fourth Quarter and Full Year 2011 Earnings Release Scheduled for February 6, 20129
. Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims10
. JBT Corporation and Swisslog Enter Into Partnership for Automated Guided Vehicles11
. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012